Hyperhemolysis syndrome in a patient without a hemoglobinopathy, unresponsive to treatment with eculizumab
Identifieur interne : 000F53 ( Main/Exploration ); précédent : 000F52; suivant : 000F54Hyperhemolysis syndrome in a patient without a hemoglobinopathy, unresponsive to treatment with eculizumab
Auteurs : Shruti Gupta [États-Unis] ; Andrew Fenves [États-Unis] ; Sandra Taddie Nance [États-Unis] ; David B. Sykes [États-Unis] ; Walter Unny Dzik [États-Unis]Source :
- Transfusion [ 0041-1132 ] ; 2015-03.
Abstract
Background: Hyperhemolysis is a serious transfusion reaction, most often described in patients with hemoglobinopathies. Hyperhemolysis is characterized by the destruction of host red blood cells (RBCs), in addition to donor RBCs, via an unknown mechanism. Study Design and Methods: We present the case of a 58‐year‐old woman with treated human immunodeficiency virus and a normal hemoglobin (Hb) electrophoresis who developed hyperhemolysis in the setting of a delayed hemolytic transfusion reaction (DHTR). Results: The patient was ABO group B and had a previously identified anti‐Fyb alloantibody. After transfusion of Fyb– RBCs, she developed a DHTR and was found to have anti‐E, anti‐Cw, anti‐s, and an additional antibody to an unrecognized high‐frequency RBC alloantigen. Subsequent transfusion of ABO‐compatible RBCs that were negative for Fyb, E, Cw, and s antigens resulted in immediate intravascular hemolysis. In the absence of bleeding, her hematocrit (Hct) decreased to 10.2%. An extensive serologic evaluation failed to identify the specificity of the high‐frequency antibody. Severe hemolytic reactions also occurred despite pretransfusion conditioning with eculizumab. The Hct and clinical symptoms slowly improved after the cessation of transfusions and treatment with erythropoietin and steroids. This case demonstrates several noteworthy features including hyperhemolysis in a patient without a Hb disorder, the development of an antibody to an unknown RBC antigen, and the failure of eculizumab to prevent intravascular hemolysis after transfusion. Conclusion: Hyperhemolysis is not restricted to patients with hemoglobinopathies. Whether eculizumab offers any benefit in the hyperhemolysis syndrome or in the prevention of intravascular hemolysis due to RBC alloantibodies remains uncertain.
Url:
DOI: 10.1111/trf.12876
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001D39
- to stream Istex, to step Curation: 001D39
- to stream Istex, to step Checkpoint: 000098
- to stream Main, to step Merge: 000F54
- to stream Main, to step Curation: 000F53
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Hyperhemolysis syndrome in a patient without a hemoglobinopathy, unresponsive to treatment with eculizumab</title><author><name sortKey="Gupta, Shruti" sort="Gupta, Shruti" uniqKey="Gupta S" first="Shruti" last="Gupta">Shruti Gupta</name></author><author><name sortKey="Fenves, Andrew" sort="Fenves, Andrew" uniqKey="Fenves A" first="Andrew" last="Fenves">Andrew Fenves</name></author><author><name sortKey="Nance, Sandra Taddie" sort="Nance, Sandra Taddie" uniqKey="Nance S" first="Sandra Taddie" last="Nance">Sandra Taddie Nance</name></author><author><name sortKey="Sykes, David B" sort="Sykes, David B" uniqKey="Sykes D" first="David B." last="Sykes">David B. Sykes</name></author><author><name sortKey="Dzik, Walter Unny" sort="Dzik, Walter Unny" uniqKey="Dzik W" first="Walter Unny" last="Dzik">Walter Unny Dzik</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:9126598165B9466030DCB6AD677E6BA3797C48EF</idno><date when="2015" year="2015">2015</date><idno type="doi">10.1111/trf.12876</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-13KSVFTT-T/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">001D39</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001D39</idno><idno type="wicri:Area/Istex/Curation">001D39</idno><idno type="wicri:Area/Istex/Checkpoint">000098</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000098</idno><idno type="wicri:doubleKey">0041-1132:2015:Gupta S:hyperhemolysis:syndrome:in</idno><idno type="wicri:Area/Main/Merge">000F54</idno><idno type="wicri:Area/Main/Curation">000F53</idno><idno type="wicri:Area/Main/Exploration">000F53</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Hyperhemolysis syndrome in a patient without a hemoglobinopathy, unresponsive to treatment with eculizumab</title><author><name sortKey="Gupta, Shruti" sort="Gupta, Shruti" uniqKey="Gupta S" first="Shruti" last="Gupta">Shruti Gupta</name><affiliation wicri:level="3"><country>États-Unis</country><placeName><settlement type="city">Boston</settlement><region type="state">Massachusetts</region></placeName><wicri:orgArea>Department of Medicine, Massachusetts General Hospital, Massachusetts</wicri:orgArea></affiliation></author><author><name sortKey="Fenves, Andrew" sort="Fenves, Andrew" uniqKey="Fenves A" first="Andrew" last="Fenves">Andrew Fenves</name><affiliation wicri:level="3"><country>États-Unis</country><placeName><settlement type="city">Boston</settlement><region type="state">Massachusetts</region></placeName><wicri:orgArea>Department of Medicine, Massachusetts General Hospital, Massachusetts</wicri:orgArea></affiliation></author><author><name sortKey="Nance, Sandra Taddie" sort="Nance, Sandra Taddie" uniqKey="Nance S" first="Sandra Taddie" last="Nance">Sandra Taddie Nance</name><affiliation wicri:level="3"><country>États-Unis</country><placeName><settlement type="city">Philadelphie</settlement><region type="state">Pennsylvanie</region></placeName><wicri:orgArea>American Red Cross Biomedical Services, Pennsylvania</wicri:orgArea></affiliation></author><author><name sortKey="Sykes, David B" sort="Sykes, David B" uniqKey="Sykes D" first="David B." last="Sykes">David B. Sykes</name><affiliation wicri:level="3"><country>États-Unis</country><placeName><settlement type="city">Boston</settlement><region type="state">Massachusetts</region></placeName><wicri:orgArea>Department of Medicine, Massachusetts General Hospital, Massachusetts</wicri:orgArea></affiliation></author><author><name sortKey="Dzik, Walter Unny" sort="Dzik, Walter Unny" uniqKey="Dzik W" first="Walter Unny" last="Dzik">Walter Unny Dzik</name><affiliation wicri:level="3"><country>États-Unis</country><placeName><settlement type="city">Boston</settlement><region type="state">Massachusetts</region></placeName><wicri:orgArea>Department of Medicine, Massachusetts General Hospital, Massachusetts</wicri:orgArea></affiliation><affiliation><wicri:noCountry code="no comma">E-mail: sdzik@partners.org</wicri:noCountry></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Transfusion</title><title level="j" type="alt">TRANSFUSION</title><idno type="ISSN">0041-1132</idno><idno type="eISSN">1537-2995</idno><imprint><biblScope unit="vol">55</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="623">623</biblScope><biblScope unit="page" to="628">628</biblScope><biblScope unit="page-count">6</biblScope><date type="published" when="2015-03">2015-03</date></imprint><idno type="ISSN">0041-1132</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0041-1132</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract">Background: Hyperhemolysis is a serious transfusion reaction, most often described in patients with hemoglobinopathies. Hyperhemolysis is characterized by the destruction of host red blood cells (RBCs), in addition to donor RBCs, via an unknown mechanism. Study Design and Methods: We present the case of a 58‐year‐old woman with treated human immunodeficiency virus and a normal hemoglobin (Hb) electrophoresis who developed hyperhemolysis in the setting of a delayed hemolytic transfusion reaction (DHTR). Results: The patient was ABO group B and had a previously identified anti‐Fyb alloantibody. After transfusion of Fyb– RBCs, she developed a DHTR and was found to have anti‐E, anti‐Cw, anti‐s, and an additional antibody to an unrecognized high‐frequency RBC alloantigen. Subsequent transfusion of ABO‐compatible RBCs that were negative for Fyb, E, Cw, and s antigens resulted in immediate intravascular hemolysis. In the absence of bleeding, her hematocrit (Hct) decreased to 10.2%. An extensive serologic evaluation failed to identify the specificity of the high‐frequency antibody. Severe hemolytic reactions also occurred despite pretransfusion conditioning with eculizumab. The Hct and clinical symptoms slowly improved after the cessation of transfusions and treatment with erythropoietin and steroids. This case demonstrates several noteworthy features including hyperhemolysis in a patient without a Hb disorder, the development of an antibody to an unknown RBC antigen, and the failure of eculizumab to prevent intravascular hemolysis after transfusion. Conclusion: Hyperhemolysis is not restricted to patients with hemoglobinopathies. Whether eculizumab offers any benefit in the hyperhemolysis syndrome or in the prevention of intravascular hemolysis due to RBC alloantibodies remains uncertain.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Massachusetts</li><li>Pennsylvanie</li></region><settlement><li>Boston</li><li>Philadelphie</li></settlement></list><tree><country name="États-Unis"><region name="Massachusetts"><name sortKey="Gupta, Shruti" sort="Gupta, Shruti" uniqKey="Gupta S" first="Shruti" last="Gupta">Shruti Gupta</name></region><name sortKey="Dzik, Walter Unny" sort="Dzik, Walter Unny" uniqKey="Dzik W" first="Walter Unny" last="Dzik">Walter Unny Dzik</name><name sortKey="Fenves, Andrew" sort="Fenves, Andrew" uniqKey="Fenves A" first="Andrew" last="Fenves">Andrew Fenves</name><name sortKey="Nance, Sandra Taddie" sort="Nance, Sandra Taddie" uniqKey="Nance S" first="Sandra Taddie" last="Nance">Sandra Taddie Nance</name><name sortKey="Sykes, David B" sort="Sykes, David B" uniqKey="Sykes D" first="David B." last="Sykes">David B. Sykes</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000F53 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000F53 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:9126598165B9466030DCB6AD677E6BA3797C48EF
|texte= Hyperhemolysis syndrome in a patient without a hemoglobinopathy, unresponsive to treatment with eculizumab
}}
| This area was generated with Dilib version V0.6.33. |  |